Advanced

Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches.

Heinonen, Suvi E; Genové, Guillem; Bengtsson, Eva LU ; Hübschle, Thomas; Åkesson, Lina LU ; Hiss, Katrin; Benardeau, Agnes; Ylä-Herttuala, Seppo; Jönsson-Rylander, Ann-Cathrine and Gomez, Maria LU (2015) In Journal of Diabetes Research 2015.
Abstract
Diabetes mellitus is a lifelong, incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease, stroke, and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). Based on the current trends, the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. Therefore, novel means to prevent and treat these complications are needed. Under the auspices of the IMI (Innovative Medicines Initiative), the SUMMIT (SUrrogate markers for Micro- and Macrovascular hard end points for Innovative diabetes Tools) consortium is working on the development of novel animal models that better... (More)
Diabetes mellitus is a lifelong, incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease, stroke, and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). Based on the current trends, the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. Therefore, novel means to prevent and treat these complications are needed. Under the auspices of the IMI (Innovative Medicines Initiative), the SUMMIT (SUrrogate markers for Micro- and Macrovascular hard end points for Innovative diabetes Tools) consortium is working on the development of novel animal models that better replicate vascular complications of diabetes and on the characterization of the available models. In the past years, with the high level of genomic information available and more advanced molecular tools, a very large number of models has been created. Selecting the right model for a specific study is not a trivial task and will have an impact on the study results and their interpretation. This review gathers information on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Diabetes Research
volume
2015
publisher
Hindawi Publishing Corporation
external identifiers
  • pmid:25785279
  • wos:000350762300001
  • scopus:84924234192
ISSN
2314-6753
DOI
10.1155/2015/404085
language
English
LU publication?
yes
id
4f71a587-c91a-4cc8-83bd-d435c018ffe4 (old id 5258232)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25785279?dopt=Abstract
date added to LUP
2015-04-05 18:58:12
date last changed
2017-10-22 03:13:36
@article{4f71a587-c91a-4cc8-83bd-d435c018ffe4,
  abstract     = {Diabetes mellitus is a lifelong, incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease, stroke, and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). Based on the current trends, the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. Therefore, novel means to prevent and treat these complications are needed. Under the auspices of the IMI (Innovative Medicines Initiative), the SUMMIT (SUrrogate markers for Micro- and Macrovascular hard end points for Innovative diabetes Tools) consortium is working on the development of novel animal models that better replicate vascular complications of diabetes and on the characterization of the available models. In the past years, with the high level of genomic information available and more advanced molecular tools, a very large number of models has been created. Selecting the right model for a specific study is not a trivial task and will have an impact on the study results and their interpretation. This review gathers information on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development.},
  articleno    = {404085},
  author       = {Heinonen, Suvi E and Genové, Guillem and Bengtsson, Eva and Hübschle, Thomas and Åkesson, Lina and Hiss, Katrin and Benardeau, Agnes and Ylä-Herttuala, Seppo and Jönsson-Rylander, Ann-Cathrine and Gomez, Maria},
  issn         = {2314-6753},
  language     = {eng},
  publisher    = {Hindawi Publishing Corporation},
  series       = {Journal of Diabetes Research},
  title        = {Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches.},
  url          = {http://dx.doi.org/10.1155/2015/404085},
  volume       = {2015},
  year         = {2015},
}